A 67-year-old man with chronic lymphocytic leukaemia (CLL) has progressive disease. According to NICE, which targeted therapy is approved for first-li...

Question

A 67-year-old man with chronic lymphocytic leukaemia (CLL) has progressive disease. According to NICE, which targeted therapy is approved for first-line treatment in symptomatic CLL if there are adverse prognostic markers?

Accepted Answer

Ibrutinib

Answer

Rituximab plus chemotherapy

Answer

Chlorambucil monotherapy

Answer

High-dose steroids

Answer

Radiotherapy to lymph nodes

MCQ (SBA): Chronic Lymphocytic Leukaemia (CLL)

A 67-year-old man with chronic lymphocytic leukaemia (CLL) has progressive disease. According to NICE, which targeted therapy is approved for first-line treatment in symptomatic CLL if there are adverse prognostic markers?